Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Herbst, Roy S, Prof, Sun, Yan, MD, Eberhardt, Wilfried EE, MD, Germonpré, Paul, MD, Saijo, Nagahiro, Prof, Zhou, Caicun, MD, Wang, Jie, MD, Li, Longyun, MD, Kabbinavar, Fairooz, MD, Ichinose, Yukito, MD, Qin, Shukui, MD, Zhang, Li, MD, Biesma, Bonne, MD, Heymach, John V, MD, Langmuir, Peter, MD, Kennedy, Sarah J, MSc, Tada, Hiroomi, MD, Johnson, Bruce E, Prof
Published in The lancet oncology (01.07.2010)
Published in The lancet oncology (01.07.2010)
Get full text
Journal Article